ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL
April 13, 2021Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, presented preclinical data at ... -
Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations
April 12, 2021Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the first ... -
Celgene invests in Chinese biotech Antengene again
January 04, 2019China’s Antengene has raised another $120 million in a second-round financing, with partner Celgene contributing to the tally....
Pharma Sources Insight January 2025
